PTC THERAPEUTICS, INC. for PTC THERAPEUTICS, INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program Issues related to Public Law No. 119-21 - The One Big Beautiful Bill Act of 2025 Issues related to international reference pricing Issues related to S. 822 and H.R. 1532 - Scientific External Process for Educated Review of Therapeutics Act of 2025
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY ARGOTE | — |
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
Medical/Disease Research/Clinical Labs MED
Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria Awareness of Duchenne Muscular Dystrophy
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY ARGOTE | — |
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
Medicare/Medicaid MMM
Innovative payment methodologies for cell and gene therapies Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to the Medicaid Drug Rebate Program Issues related to implementation of Public Law No. 117-169 - The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 946 - The Optimizing Research Progress Hope and New Cures Act and the small molecule penalty, including H.R. 1492 - The Ensuring Pathways to Innovative Cures Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY ARGOTE | — |
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
Taxation/Internal Revenue Code TAX
Issues related to Section 174 R&D Amortization, including H.R. 1990 - American Innovation and R&D Competitiveness Act of 2025 Issues related to the Orphan Drug Tax Credit, including H.R. 1414 - Camerons Law
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY ARGOTE | — |
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
Trade (domestic/foreign) TRD
Issues related to tariffs
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY ARGOTE | — |
| NICHOLAS BRAUGHTON | — |
| JONATHAN REA MCPHERSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.